The Prevalence of Depression and Anxiety in Women With Ovarian Cancer: An Updated Systematic Review and Meta-Analysis of Cross-Sectional Studies Publisher Pubmed



Ghamari D¹ ; Dehghanbanadaki H² ; Khateri S³ ; Nouri E³ ; Baiezeedi S⁴ ; Azami M¹ ; Amini EE³ ; Moradi Y³
Source: Asian Pacific Journal of Cancer Prevention Published:2023

Abstract

Background: The results of this study included the prevalence of anxiety and depression in women with ovarian cancer. Methods: A thorough search of numerous databases, including PubMed (Medline), Scopus, Web of Science, Embase, and PsycoInfo, was conducted to identify relevant cross-sectional studies published between July 2013 and October 2021. STATA 16 was used to analyses the data, and a random effects model was used to determine the pooled prevalence and a 95% confidence interval (95%CI). Results: Of the 18 cross-sectional studies reviewed, 17 reported the prevalence of anxiety and 16 reported the prevalence of depression in patients with ovarian cancer. There was a moderate degree of heterogeneity between studies, as the pooled prevalence of depression was 27% (95%CI: 14%-41%; I2=69.44%). Similarly, there was a greater degree of heterogeneity in the pooled prevalence of anxiety, which was found to be 33% (95%CI: 21%-44%; I2=78.55%). Conclusion: The findings of this study show that, compared to the overall female population, ovarian cancer patients have much greater rates of sadness and anxiety. These results highlight the necessity for healthcare policymakers to prioritize the provision of resources and support for carrying out additional research, such as longitudinal studies or cohorts, to ascertain the efficacy of various treatments or interventions intended to lessen mental health disorders in women diagnosed with ovarian cancer. Healthcare practitioners can enhance the general wellbeing and quality of life for women with this disease by addressing the psychological components of care. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License